• FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients
  • 1,066 Myeloma Patients Answer HealthTree Survey of COVID-19’s Effects
  • FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
  • Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows
  • Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo
  • Belantamab Mafodotin Continues to Show Promise in Advanced Myeloma Trials
  • JNJ-4528 Continues to Show Strong, Durable Responses in Trial
  • Phase 3 Trial of Melflufen Combo in Advanced Multiple Myeloma Fully Enrolled
  • UK’s NICE Issues Draft ‘No’ Decision for Sarclisa Triple Combo
  • Xpovio Triple Combo Before FDA for Previously Treated Myeloma Patients
  • New Under-the-skin Darzalex Formulation Approved in EU
  • Sarclisa Triple Combo Approved in Europe for Advanced Myeloma Patients